JAPAN does not forgive generic strategy.

De-risk your multimillion-dollar market entry with the only clinician-led commercial architecture firm in APAC.

Strategic Talent Architecture • Clinical Adoption • Commercial Traction

discuss a project
advisory seats

the silent failure of healthcare expansion

Global innovators don't fail in Japan because their technology is bad. They fail because they treat Japan as "just another territory."

  • The Talent Gap: You hire a "safe" Country Manager who manages the status quo but cannot scale.

  • The Clinical Disconnect: You have the regulatory approval, but the KOLs aren't prescribing.

  • The Commercial Plateau: Your distributor is collecting a margin while your brand equity rots.

The Verdict: If you do not have Clinical Credibility aligned with Commercial Aggression, you are not investing—you are donating.

clinician-led. commercially proven.

We are not recruiters. We are Commercial Architects.

Founded by Emilio Campos, D.D.S.: Strategy that speaks the language of your customers (Clinicians).

  • 26+ Years Ecosystem Depth: Deep networks in Japan, Korea, & APAC.

  • Full-Stack Execution: From Genomics, Oncology & Rare Disease, MedTech to Digital Health & Medical Aesthetics.

  • Proven Speed: We deliver actionable 1-page war plans, not 100-page academic novels.

the 3-pillar growth engine


STRATEGIC TALENT

The Foundation

We don't just fill seats. We engineer the leadership team necessary to execute the P&L.

  • Delivers: Executive Search, Org Chart Design, Compensation Strategy.


CLINICAL ADOPTION

The Moat

Leverage a clinician perspective to validate product-market fit and secure the KOLs that drive adoption.

  • Delivers: KOL Mapping Sprints, Clinical Market Validation, PMDA Advisory.

COMMERCIAL TRACTION

The Revenue

Navigate the distributor vs. direct maze and break through revenue plateaus.

  • Delivers: Launch Playbooks, Turnaround Audits, Distribution Channel Strategy.


deploymet architecture

We reject hourly billing. we engage via defined outcomes or retained access.

FOCUSED SPRINT

For: Market Entrants & Scalers requiring a specific commercial unlock.

The Deliverable: A defined, 90-day tactical engagement to execute one of our Core Pillars (Talent, Clinical, or Traction).

  • Scope: Fixed & Finite.

  • Velocity: High-Speed Execution.

  • Outcome: 1-Page Playbook + Key Hires/KOLs Secured.

Ideal For:

  • Building the initial Launch Team.

  • Mapping & Engaging the first 10 KOLs.

  • Auditing a failing Distributor channel.

RETAINED ADVISORY

(Limited Capacity: 2 Seats Available)

For: Founders and P&L Owners who need on-demand strategic air cover without the operational drag of a full consulting engagement.

The Access:

  • Direct Line: Direct access to Emilio Campos, D.D.S.

  • Cadence: Bi-weekly strategic calibration + Async comms.

  • Crisis Mgmt: "Red Phone" priority for critical decisions.

Ideal For:

  • De-risking investor updates & board strategy.

  • Sanity-checking local team performance.

  • Navigating complex regulatory/clinical pivots.

trusted by the p&L owners of:

Dental, Regen Med, Med Aesthetics

Straumann
Nobel Biocare
Dentsply Sirona
Align Technology
Geistlich Pharma
ZO Skin Health
Establishment Labs
Milteny Biotec
Sony Biotechnology
Leica Biosystems
Kimberly Clark HC
UCB Japan

What Our Partners Are Saying…

"Re-entering Japan after a difficult distributor partnership felt like starting from zero. We had no team and a stalled growth trajectory in our second-largest market. Inoventic didn't just find candidates; they served as our strategic partner, building our entire commercial and operational team from the ground up. They understood our uniquely complex talent needs and delivered the 10 leaders who turned our business around, allowing us to hit our ambitious scale-up targets."

— SVP, Global Aesthetics Company

Scientific & Diagnostics

Illumina
Thermo Fisher Scientific
Bio-Rad Laboratories
Qiagen
Beckman Coulter
Sysmex
Hologic
Bruker
AB Sciex
Nova Biomedical
Mettler Toledo

Broader MedTech & Pharma Ecosystem

Merck
Teva Takeda Pharma
LONZA
Almac
Covance
EPS
Hitachi Hi-Tech
IDEXX Laboratories
Eurofins Genomics
FOSS
Catalent
A.D.A.M. Innovations

"We chose Japan as the global launchpad for our game-changing new technology, which came with immense investor pressure and zero room for error. The standard commercial profile wasn't a fit for our sensitive category. Inoventic understood this perfectly and secured the two foundational leaders—our APAC Head of Medical Education and Brand Manager—who were instrumental in our success. Their work directly contributed to a successful clinical launch, positive KOL engagement, and a significant increase in our stock price."

— CEO, US-Based FemTech Innovator

"We were at a critical inflection point, facing immense investor pressure to transform our consumer genomics company into a regional, AI-driven data platform for a potential IPO. This required a complete overhaul of our leadership and culture. Inoventic was the strategic partner who architected our new executive dream team. They brought us the A-list leaders—our new CMO, CTO, CSO, and Heads of Comms and PR from companies like Google and Mercari—who laid the foundation to transform our business model and position us as the undisputed leader in our market."

— Board Member, APAC-based Genomics AI Company

Most failures are scripted 18 months before launch. Download the diagnostic used by P&L owners to audit their Japan strategy.

before you enter japan.

get the audit